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Abstract A recurrent theme in viral immune evasion is the sabotage of MHC-I antigen
presentation, which brings virus the concomitant issue of ‘missing-self’ recognition by NK cells that
use inhibitory receptors to detect surface MHC-I proteins. Here, we report that rodent herpesvirus
Peru (RHVP) encodes a Qa-1 like protein (pQa-1) via RNA splicing to counteract NK activation.
While pQa-1 surface expression is stabilized by the same canonical peptides presented by murine
Qa-1, pQa-1 is GPI-anchored and resistant to the activity of RHVP pK3, a ubiquitin ligase that
targets MHC-I for degradation. pQa-1 tetramer staining indicates that it recognizes CD94/NKG2A
receptors. Consistently, pQa-1 selectively inhibits NKG2A+ NK cells and expression of pQa-1 can
protect tumor cells from NK control in vivo. Collectively, these findings reveal an innovative NK
evasion strategy wherein RHVP encodes a modified Qa-1 mimic refractory to MHC-I sabotage and
capable of specifically engaging inhibitory receptors to circumvent NK activation.
DOI: https://doi.org/10.7554/eLife.38667.001
Introduction
Herpesviruses are large double-stranded DNA viruses that are associated with malignancies and can
persist in the presence of an active immune system in part through their ability to avoid detection by
both cytotoxic T lymphocytes (CTL) and NK cells (Odom et al., 2012; Feng et al., 2013;
Noriega et al., 2012), two major branches of host cellular defense in adaptive and innate immunity,
respectively. CTL detect foreign antigens presented by major histocompatibility complex class I
(MHC-I) by engagement of their TCR with MHC-I/peptide complexes on the surface of target cells.
The importance of CTL function in control of viral infection is highlighted by numerous examples of
viral proteins disrupting MHC-I antigen presentation pathways (Hansen and Bouvier, 2009). In con-
trast to CTL, functional NK cells can respond and kill viral infected cells rapidly without the need for
priming and expansion. NK cells are also vital in the control of herpesvirus infection. In humans, for
example, individuals with selective NK cell deficiencies, either in number or function, often exhibit
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recurrent and severe herpesvirus infections including a herpesviruses (VZV, HSV), b herpesviruses
(CMV) and g herpesviruses (EBV) (reviewed in (Orange, 2013)). Similarly, NK cell-depletion confers
susceptibility upon inbred strains of mice otherwise resistant to murine cytomegalovirus (MCMV)
infection (Scalzo et al., 1992). The pivotal role of NK cells in host defense to viral infection is also
underscored by the co-evolutionary development of viral NK evasion strategies and NK receptor
expansions (Carrillo-Bustamante et al., 2016).
NK cell activity against viral-infected targets is balanced by integrated signals from inhibitory and
activating receptors. In addition to presenting peptides that activate antigen-specific CTL, MHC-I
molecules also serve as ligands for NK cell inhibitory receptors. The normal, ubiquitous expression
of MHC-I protects healthy cells from NK killing. When MHC-I antigen presentation is sabotaged by
pathogens, NK cells are released from inhibition and consequently may attack infected cells. The
loss of surface MHC-I is often referred to a ‘missing-self’ (Jensen et al., 2004; Yokoyama et al.,
2010; Natarajan et al., 2002). Thus, in the battle against viral infections, cell surface MHC-I plays a
pivotal role in regulating CTL and NK cells and thereby both adaptive and innate immunity. This
defense strategy presents a challenge for the virus; to avoid CTL detection, it must downregulate
MHC-I surface expression, yet at the same time it must avoid triggering NK cell activation due to
‘missing-self’.
Not surprisingly, along with their CTL evasion mechanisms, many viruses have also evolved strate-
gies for coping with ‘missing-self’ attack by NK cells. One such strategy is the selective upregulation
of surface expression of HLA-E in humans and Qa-1 in mice, the non-classical MHC-I proteins that
serve as ligands for the NK cell inhibitory receptor CD94/NKG2A. For example, UL40 encoded by
human cytomegalovirus (HCMV) selectively stabilizes surface HLA-E by providing a nonameric pep-
tide that is loaded on to HLA-E in the ER yet independent of transporter associated with antigen
processing (TAP) (Tomasec et al., 2000; Ulbrecht et al., 2000). Other viral immune evasion proteins
such as HCMV US2 and US11, Kaposi’s sarcoma-associated herpesvirus (KSHV) kK5, and HIV nef,
induce profound downregulation of classical MHC-I but do not compromise HLA-E expression
(Orange et al., 2002).
The CD94/NKG2 family of receptors are type-II transmembrane heterodimers that possess C-type
lectin ectodomains. They are conserved in humans and mice and expressed on large percentages of
NK cells (Petrie et al., 2008; Hoare et al., 2008). Each member of this family comprises an invariant
CD94 polypeptide disulfide linked to either NKG2A/B, -C, -E or -F. NKG2A and -B (a spliced form of
–A) are inhibitory whereas NKG2C and -E are activating NK receptors (Kaiser et al., 2005;
Braud et al., 1998b; Lazetic et al., 1996). The functional nature of NKG2F has not been deter-
mined. An evolutionary analysis across primates revealed that both NKG2A and NKG2C are evolving
under positive selection, suggesting that both genes have been actively engaged in host-pathogen
conflict throughout primate evolution (Kaiser et al., 2008). Notably, although the inhibitory and the
activating NKG2 receptors are both specific for HLA-E or Qa-1 that in normal circumstances presents
peptides dominantly derived from signal sequences of other MHC class I molecules (Bai et al.,
1998; Llano et al., 1998; Braud et al., 1998a), the binding affinity of inhibitory CD94/NKG2A
receptor to HLA-E appears higher than for the activating receptors CD94/NKG2C and NKG2E
(Kaiser et al., 2005; Vale´s-Go´mez et al., 1999), and the expression of NKG2C/E normally is
extremely low (Vance et al., 1999). Thus, engagement of peptide HLA-E/Qa-1 complex with CD94/
NKG2 receptors in normal circumstances is believed to dominantly maintain self-tolerance and to
sense aberrancy in MHC-I production.
Compared to b herpesviruses, like HCMV and MCMV, the importance of NK cells in
g herpesvirus infection is less well understood. Opportunities to address this issue have come from
the identification of rodent herpesvirus Peru (RHVP) that was isolated from a lung homogenate of a
pygmy rice rat (Oligoryzomys microtis) caught in Peru (Loh et al., 2011). RHVP is a member of the
rhadinovirus genus of g herpesviruses along with KSHV and gHV68. RHVP can establish latent infec-
tion in normal B6 and 129 mice, suggesting immune evasion mechanisms are utilized by the virus.
Indeed, RHVP encodes several unique ORFs that are not present in other g herpesviruses and
appear to have immune evasion functions (Lubman et al., 2014; Lubman and Fremont, 2016). We
previously reported that the R12 protein encoded by RHVP, termed pK3 because of its similarities to
the K3 proteins of KSHV and gHV68, is a MARCH (membrane-associated RING-CH) family E3 ubiqui-
tin ligase that induces rapid degradation of MHC-I by direct interaction with the heavy chain trans-
membrane (TM) region in the ER (Herr et al., 2012). In addition, pK3 secondarily induces profound
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loss of the MHC-I-dedicated chaperone tapasin as well as TAP. Thus, pK3 uses a multi-pronged
attack to potently downregulate surface MHC-I. This ability to dramatically reduce antigen presenta-
tion to CTL raises the question of how RHVP copes with ‘missing self’ recognition by NK cells.
In this paper, we report the discovery and characterization of an RHVP encoded Qa-1 mimic that
can inhibit NK activation. In contrast to Qa-1, pQa-1 lacks a canonical TM region and cytoplasmic
tail, and is instead GPI anchored, which confers resistance to downregulation by RHVP pK3. Similar
to cellular Qa-l, pQa-1 interacts with the CD94/NKG2A inhibitory receptor. Expression of pQa-
1 inhibits NK activation in vitro and protects tumor cells from NK control in vivo. In addition, we
demonstrate that pK3-induced loss of surface MHC-I renders cells susceptible to syngeneic NK kill-
ing, whereas concomitant co-expression of pQa-1 reduces cell susceptibility to NK killing in a
NKG2A-dependent manner. Thus, our findings demonstrate that RHVP employs compensatory
mechanisms to concurrently sabotage CTL and NK-mediated immunity.
Results
RHVP encodes a Qa-1-like protein that requires RNA splicing for
expression
Our previous findings that pK3 of RHVP potently downregulates surface MHC-I to ablate antigen
presentation to CTL (Herr et al., 2012) raised the question for how RHVP evades ‘missing self’
attack by NK cells. With this in mind, we were intrigued to find that the 5’ end of the RHVP genome
(1383 to 236 nucleotides in reverse direction) contains a cluster of three previously annotated ORFs
(R3, R2 and R1) with high similarity to MHC-I a1, a2 and a3 domains, respectively (Loh et al., 2011).
More strikingly, two putative introns that flank consensus splicing donor/acceptor sites (Keller and
Noon, 1984) were detected in between the putative a1 and a2, as well as the a2 and a3 coding
sequences (Figure 1A, upper panel). To test whether the genomic sequence 1383 to 236 nucleoti-
des could be processed by RNA splicing into one mature mRNA encoding a complete MHC-I-like
protein, total RNA was prepared from RHVP-infected IFNabgR-/-mouse embryonic fibroblast (MEF)
cells 24 hr post-infection, from which the first strand cDNA pool was then obtained by RT-PCR using
oligo dT. The sequences amplified by PCR from the cDNA pool using a forward primer to the 5’ end
of R3 and a reverse primer to the 3’ end of R1 was consistent with predicted splicing events (Fig-
ure 1—figure supplement 1–1A and S1B). In these splicing events, the two introns containing 88
and 82 nucleotides, respectively, were excised (Figure 1A, upper panel). This organization of exons
and introns is analogous to mammalian MHC-I genes as exemplified by the mouse Qa-1 gene
(Figure 1A, lower panel), suggesting that this ORF (here annotated as pQa-1) originated as a hori-
zontal transfer from the host to the virus. Notably, the pK3 coding sequence was also concurrently
amplified from the cDNA pool using primers specific to the ORF of pK3, suggesting the two proteins
are co-expressed within 24 hr post-infection (Figure 1—figure supplement 1–1C).
The Qa-1-like protein is associated with b2m and expressed on the cell
surface as a GPI anchored protein
Sequence comparisons using the putative mature viral protein after signal peptide cleavage (resi-
dues 1–280 corresponding to the a1–3 ectodomains) yielded strong similarity to Qa-1 proteins
(>56% identity) from mouse, rat, hamster and vole and slightly less strong similarity to some classical
MHC-I proteins from human, monkey, panda, wild boar and harbor seal (54–52% identity)
(Supplementary file 1). Furthermore, phylogenetic analysis revealed that this viral MHC-I-like pro-
tein shares more similarity with rat and mouse Qa-1 than human HLA-E or mouse/human classical
MHC-I (Figure 1B). Similar to Qa-1, it contains substitutions of Ser and Leu at the Thr143 and
Trp147 residues that contribute to peptide binding in the F pocket of classical MHC-I (Figure 1—fig-
ure supplement 1–2). We therefore designated this RHVP-encoded protein as pQa-1 and specu-
lated that it may be a mimic of Qa-1 capable of interacting with CD94/NKG2 receptors. However, it
should be noted that distinct from Qa-1, pQa-1 was not predicted to have a canonical TM region or
a C-terminal cytoplasmic tail. Instead, it was predicted by GPI-SOM (Fankhauser and Ma¨ser, 2005)
to potentially be GPI anchored at residue 290 (Figure 1A, upper panel).
Because multivalent surface expression is expected to be needed for signaling via interaction
with CD49/NKG2 receptors on NK cells, we next examined whether pQa-1 is surface expressed.
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Figure 1. RHVP encodes a Qa-1-like protein. (A) Schematic comparison of the regions encoding RHVP pQa-1 and
mouse H2-Qa-1. The genomic sequence is represented by a black line (solid for mouse and dotted for virus), and
genome coordinates are indicated below. The exons of the translated regions of the RHVP genome and the
mouse Qa-1 gene (NC_000083.6) are represented by dotted and solid black block, respectively. (B) Unrooted
phylogenetic tree of the proteins, including RT-BM1: rat MHC-Ib-S3 (NP_001008886.2); H2-T11: mouse H2-T11
(NP_001257934); H2-Qa1(a), -Qa1(c), -Qa1(b) and -Qa1(d): mouse Qa-1a (XP_003945787), Qa-1c (AAD12244.1), Qa-
1b (NP_034528) and Qa-1d (AAD31381); HLA-E: human HLA-E (NP_005507.3); HLA-B: human HLA-B7 (AAA91229);
HLA-C: human HLA-Cw0702 (CAA05125); HLA-A: human HLA-A2 (ASA47534); H2-Kd: mouse H2-Kd (P01902.1); H2-
Ld: mouse H2-Ld (P01897.2); H2-Dd: mouse H2-Dd (P01900.1); RT1-A1: rat MHC-Ia-A1 (NP_001008827.1); RT1-A2:
rat MHC-Ia-A2 (NP_001008829); RT1-A3: rat MHC-Ia-A3 (NP_001008830); RT1-M3: rat MHC-Ib-M3 (NP_075210.2);
H2-M3: mouse H2-M3 (AAA39597), was created using PHYLIP Neighbor Joining algorithm (http://evolution.
genetics.washington.edu/phylip/phylipweb.html). Horizontal branch lengths reflect the number of nucleotide
substitutions per site.
DOI: https://doi.org/10.7554/eLife.38667.002
Figure 1 continued on next page
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Since there was no specific antibody available, an HA tag was engineered into pQa-1 between the
putative a3 domain and a 26 residue long C-terminal peptide predicted to contain sequences neces-
sary for recognition by cellular GPI anchor machinery (Figure 2A). A retroviral IRES-GFP vector was
used to stably transduce cells to express pQa-1-HA (hereafter referred to as pQa-1). Low levels of
surface pQa-1 in mouse and human cells were detected by flow cytometry using an anti-HA antibody
(Figure 2B). This low level expression of viral pQa-1 is similar to what has been reported for mouse
Qa-1 (Gays et al., 2001). To test whether the C-terminal peptide of pQa-1 could be recognized as a
GPI anchor signal, a chimeric molecule with the a1–3 of H2-Ld fused to the 26 residue C-terminal
peptide of pQa-1 (designated Ld-pQa-1) was also constructed and stably expressed on MEFs
(Figure 2A). Surface levels of pQa-1 and Ld-pQa-1 but not wild type Ld were both reduced upon a
low dose GPI-cleaving enzyme phosphatidylinositol-specific phospholipase C (PI-PLC) treatment,
indicating that both proteins were cell surface tethered via GPI anchors (Figure 2C, left panels). The
sensitivity of Ld-pQa-1 to PI-PLC treatment was dose dependent and the extent of reduction in fluo-
rescence signal upon treatment with different doses of PI-PLC is similar to that of a known GPI-
anchored protein, Thy1.1, expressed on the same cells (Figure 2C, right panels). Further, we found
that pQa-1 was associated with b2-microblobulin (b2m) by labeling pQa-1-expressing cells with [35S]
Cys/Met followed by immunoprecipitation of pQa-1, or by immunoprecipitation of pQa-1 followed
by western blot of b2m (Figure 2D, left and right panel, respectively). In addition, we found that
without b2m in a H2-Kb-/-, H2-Db-/- and B2m-/- MEF line (designated 3KO) pQa-1 was barely
detected, while reconstitution of b2m into 3KO cells by retroviral transduction clearly enhanced sur-
face expression of pQa-1 (Figure 2E), indicating that endogenous b2m is required for surface
expression of pQa-1.
Qdm or Qdm-like peptides stabilize pQa-1 in a manner similar to mouse
Qa-1
One of the hallmarks of Qa-1 is its propensity to preferentially bind the peptide AMAPRTLLL (also
called Qa-1 determinant modifier or Qdm) derived from the leader sequence of H2-D or H2-L in a
TAP-dependent manner (DeCloux et al., 1997; Bai et al., 1998). NK cytotoxicity can be inhibited by
the engagement of CD94/NKG2A with its ligand Qa-1 and this inhibitory effect is highly dependent
on Qa-1 being loaded with the Qdm peptide (Kraft et al., 2000). Based on this and sequence simi-
larity of pQa-1 to Qa-1, we tested whether pQa-1 also binds Qdm or Qdm-like peptides. To assess
binding, we performed surface stabilization assays using pQa-1-expressing cells cultured with either
Qdm or a control H2-Kb binding peptide (ovalbumin residues 257–264, OVA). A modest but signifi-
cant enhancement in pQa-1 levels was observed when co-cultured with Qdm but not the OVA pep-
tide at 37˚C for 4 hr, although the OVA peptide enhanced the level of surface Kb on the same cells
as reported (Figure 3A).
RHVP was first isolated from a pygmy rice rat trapped in Peru (Loh et al., 2011). Since the distri-
bution of additional hosts is unknown, we attempted to identify a binding peptide for pQa-1 from a
group of Qa-1-like candidates found in the MHC-I of different species or in some viral proteins
(Supplementary file 2). Surface levels of pQa-1 were significantly enhanced when cells were cul-
tured at 27˚C for 4 hr with Qdm or with the Qdm-like nonamers that have one residue difference at
the P1, P2 or P3 position compared to no peptide added (Figure 3B). In contrast to the nonamers,
an octameric peptide that lacks the P1 residue of Qdm did not increase surface pQa-1. This analysis
suggests that pQa-1 prefers to bind a Qdm-like nonamer and tolerates certain variations in peptide
sequence. This is very similar to the observations made with mouse Qa-1 where single substitution
with G/A at P1 and P3 or K at P1 in Qdm did not appear to impact peptide binding (Kurepa and
Figure 1 continued
The following figure supplements are available for figure 1:
Figure supplement 1. Three previously annotated RHVP ORFs are spliced to form mRNA encoding an MHC-I-like
protein.
DOI: https://doi.org/10.7554/eLife.38667.003
Figure supplement 2. Sequence alignment of pQa-1 with selected classical and non-classical MHC-I proteins.
DOI: https://doi.org/10.7554/eLife.38667.004
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Figure 2. RHVP pQa-1 is GPI anchored, cell surface expressed and assembles with b2m. (A) Schematic depiction of the pQa-1 expression constructs
used in the study. The C-terminal 26aa containing predicted GPI attachment site (marked by red star) is shown under the C-terminus of the last
construct. (B) Mouse embryonic fibroblast (MEF) and human 293 T cells were stably transduced with the vector only or pQa-1-HA construct depicted in
(A). Surface expression of pQa-1 on these cells was analyzed by flow cytometry using anti-HA antibody. (C) Left panel: cells were treated with (blue) or
without (red) 0.069 U/ml phosphatidylinositol-specific phospholipase C (PI-PLC) at 37˚C for 45 min before staining with anti-HA or anti-Ld (30-5-7). MEFs
expressing vector only served as background staining (solid gray). The representative of two independent experiments is shown. Right panel: following
incubation with indicated concentration of PI-PLC, MEF cells expressing Ld-pQa-1 or Thy1.1 were examined. Here endogenous MHC-I (H2–Kb) serves as
a negative control protein; its level of surface expression was unaffected by PI-PLC. (D) Following a 30-min pulse with 35S-Cys/Met, pQa-1 transduced
MEF cells were lysed with 1% NP-40 and immunoprecipitated for pQa-1 using anti-HA. The precipitated proteins were resolved on SDS-PAGE and
visualized by autoradiography (left) or immunoblotted with the indicated antibodies (right). The representative of two independent experiments is
shown. (E) MHC-Ia- and b2m-deficient MEFs (H2-Kb-/- H2-Db-/- B2m-/-; 3KO) or 3KO+b2m cells transduced with pQa-1-HA or vector control were
examined for surface pQa-1 expression using anti-HA. The representative of two analyses is shown.
DOI: https://doi.org/10.7554/eLife.38667.005
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Forman, 1997; Kraft et al., 2000). These data indicate that pQa-1 maintains similar peptide-binding
properties as Qa-1.
It is noteworthy that surface pQa-1 in stably transduced cells increased after IFNg treatment
(Figure 3C). Since expression of transduced pQa-1 was not controlled by an MHC-I promoter, this
enhancement could not be explained by IFNg promoted MHC-I production. Instead, it may be an
indirect consequence of IFNg-induced increase in b2m or/and source of stabilizing peptides. We also
Figure 3. Qdm and Qdm-like peptides stabilize pQa-1 at the cell surface. (A) Following incubation of MEF-pQa-1cells with 100 mM Qdm (AMAPRTLLL)
or OVA257-264 (SIINFEKL) peptide at 37˚C for 4 hr, surface pQa-1 and H2-Kb were analyzed by flow cytometry for comparison. (B) MEF-pQa-1were
incubated with the indicated peptide (100 mM) at 27˚C for 4 hr before staining for surface pQa-1. (C) Surface pQa-1 was FACS analyzed after incubation
with 100 U/ml IFNg for 24 hr. (D) Surface pQa-1 in a stably transduced TAP1-deficient (Tap1-/-) fibroblast line was detected by FACS after incubation
with or without 100 U/ml IFNg for 40 hr. Representative of two analyses with mean ±SD of duplicates is shown. Bars in the figures represent mean ±SEM
of two (C) or three (A and B) independent analyses using unpaired t test or one-way ANOVA, Dunnett’s multiple comparisons test to compare with no
peptide controls (*=p < 0.05; **=p < 0.01; ***=p < 0.001; ****=p < 0.0001; ns = not significant). Endogenous MHC-I Kb in these cells served as positive
control.
DOI: https://doi.org/10.7554/eLife.38667.006
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examined whether pQa-1 is expressed on the surface of TAP-deficient cells. We found, similar to
what we had observed with wildtype MEF cells, that TAP1-deficient fibroblasts stably transduced
with pQa-1 express a low level on the cell surface, and this level can be enhanced by IFNg treatment
(Figure 3D). Given the role peptide loading is known to play in MHC-I quality control, we would not
expect pQa-1 to be efficiently released from the ER to the surface or to survive long at the cell sur-
face without first being loaded with peptide. Thus, expression of pQa-1 on TAP-deficient cells sug-
gests pQa-1 can load peptide independently of TAP as has been seen for Qa-1 and HLA-E
(Lampen et al., 2013; Oliveira et al., 2010). Thus, during RHVP infection, surface pQa-1 levels could
be correlated with the infection-induced IFNg production even when TAP function is impaired.
pQa-1 is resistant to RHVP pK3-induced degradation
We previously demonstrated that pK3, a MARCH family E3 ligase encoded by RHVP, efficiently
downregulates surface MHC-I by targeting newly synthesized MHC-I in the ER for rapid, ubiquitina-
tion-mediated degradation (so called ER-associated degradation, ERAD) (Herr et al., 2012). In con-
trast to mK3 of gHV68 that directly interacts with TAP to capture TAP-associated MHC-I, pK3
targets MHC-I through direct interaction with the TM region of MHC-I proteins. Newly synthesized
pQa-1 includes a hydrophobic tail that is thought to be transiently embedded in the membrane
before cleavage and GPI-linkage to the newly generated C terminus (Udenfriend and Kodukula,
1995). While the initial hydrophobic tail of pQa-1 does not have any appreciable sequence similarity
to either Qa-1 or MHC-I proteins, we nevertheless sought to examine whether it might be resistant
to pK3-mediated degradation. To test this, MEF cells expressing Qa-1 or pQa-1 were co-transduced
with either wildtype pK3 (pK3 WT) or a pK3 RING mutant (pK3 RM) that loses ligase activity while
retaining the ability to associate with the target. Indeed, in the presence of pK3 WT, Qa-1 was signif-
icantly down regulated, like classical MHC-I, even though Qa-1 was not as well expressed as pQa-1
in these experiments (Figure 4A, lower panel). Downregulation of Qa-1 by pK3 was more evident
with higher baseline expression of endogenous Qa-1 in RMA cells (Figure 4B). In contrast, surface
pQa-1 remained unchanged in the presence of pK3 (Figure 4A, upper panel). Importantly, downre-
gulation of MHC-I and Qa-1 was not observed in the presence of the catalytically inactive pK3 RM,
demonstrating that E3 ubiquitin ligase activity was required. In addition, the GPI anchored classical
MHC-I chimera, Ld-pQa-1, was resistant to pK3, whereas the reciprocal chimera with a1-a2 domains
of pQa-1 and a3-TM-cytoplasmic tail of Ld (pQa-1-Ld) remained as sensitive to pK3 as wild type Ld
(Figure 4C), supporting the conclusion that pQa-1 resistance to pK3 is associated with its unique
C-terminal tail. Based on these observations we speculate that pQa-1 evolved to counteract NK acti-
vation caused by the MHC-I downregulation by pK3.
The CD94/NKG2A receptor specifically detects pQa-1/Qdm complexes
The sequence similarity and peptide-binding similarities of pQa-1 with Qa-1 suggest that it may be a
ligand for CD94/NKG2 receptors on NK cells. Intriguingly, the CD94/NKG2 family consists of the
inhibitory receptor CD94/NKG2A as well as activating receptors CD94/NKG2C and CD94/NKG2E.
All these heterodimeric receptors have the same ligand, Qa-1 (HLA-E in humans). Antibodies that
are capable of distinguishing different forms of NKG2 receptors are currently unavailable, thus the
relative distribution and expression of the inhibitory versus activating NKG2 receptors remains
poorly characterized. Nevertheless under normal circumstances expression of NKG2C or NKG2E at
the mRNA level is much lower than NKG2A (Vance et al., 1999) and in NKG2A-/- mice, surface
NKG2C is undetectable (Rapaport et al., 2015). With this background, we first tested whether
recombinant pQa-1 tetramers detect CD94/NKG2 positive cells. To circumvent difficulties encoun-
tered in production of soluble pQa-1 proteins due to instability of peptide/pQa-1/b2m complexes,
we expressed Qdm-b2m-pQa-1 as a single chain trimer (pQa-1-SCT) either GPI anchored or soluble
with a biotin label at the C terminus (depicted in Figure 5—figure supplement 5–1A). To secure
the Qdm peptide in the binding groove, we also engineered a disulfide trap between the first linker
G2C and residue Y84C of the pQa-1 (pQa-1-dtSCT). As we previously observed with classical MHC-I
(Mitaksov et al., 2007; Truscott et al., 2007), the pQa-1-SCT appeared to be more stable than
pQa-1. The surface levels of GPI anchored pQa-1-SCT and pQa-1-dtSCT were 6–8 folds higher than
pQa-1 expressed alone (Figure 5—figure supplement 5–1A); and their thermostabilities as mea-
sured by circular dichroism melting analysis were comparable to those reported for classical MHC-I
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Figure 4. Qa-1 is sensitive to pK3-induced downregulation while pQa-1 is resistant. (A) MEF-pQa-1 (upper panel) or MEF-Qa-1 (lower panel) cells were
transduced with vector, pK3 or pK3 RING mutant (pK3 RM). Surface pQa-1/Qa-1 levels were determined by anti-HA/anti-Qa-1 staining. Surface
expression of endogenous MHC-I Kb on these cells served as a positive control of pK3 function. (B) Surface expression of endogenous Qa-1 on RMA
cells in the presence of vector, pK3 or pK3 RM were analyzed similarly. (C) Surface levels of classical MHC-I Ld, chimeric Ld-pQa-1 or chimeric pQa-1-Ld
Figure 4 continued on next page
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Kb-SCT (Figure 5—figure supplement 5–1B and Mitaksov et al., 2007). Using soluble pQa-1-
dtSCT, we next generated tetramers to stain mouse spleen cells. These pQa-1-dtSCT tetramers
stained the same population recognized by the NKG2A/C/E antibody (Figure 5). This population
consisted of about 40% of NK cells and 2% of CD8+ T cells in the splenocytes isolated from wildtype
C57BL/6 mice. Also similar to the level of anti-NKG2A/C/E antibody staining, the median fluores-
cence intensity (MFI) of tetramer+ CD8+ cells was lower than NK cells. Furthermore, in contrast to
the wildtype mice, NK and CD8+ cells from NKG2A-/- mice were not stained by pQa-1-dtSCT tetra-
mer or the NKG2A/C/E antibody (Figure 5). Thus, pQa-1 is able to selectively engage CD94/NKG2
receptors on murine cytotoxic cells.
To further determine whether pQa-1 differentially interacts with inhibitory and activating NKG2
receptors, we evaluated cells co-expressing CD94 and either the NKG2A or NKG2C ectodomain
with the TM and cytoplasmic regions of NKG2C (Figure 5—figure supplement 5–2A). Since expres-
sion of CD94 alone indicated by appearance of GFP was not detected by CD94 antibody in flow
cytometry (Figure 5—figure supplement 2B), we used CD94 staining to monitor the level of the
heterodimeric receptors on the cells. Using this system, we found that both the NKG2A/C/E anti-
body and pQa-1-dtSCT tetramer strongly stained the cells expressing CD94/NKG2A, but both
reagents poorly stained cells expressing CD94/NKG2C. Nevertheless, reasonable levels of CD94
were detected in both lines (Figure 5—figure supplement 2C). While it is possible that pQa-1-
dtSCT preferentially binds the inhibitory CD94/NKG2A rather than activating CD94/NKG2C recep-
tor, the low level of NKG2A/C/E antibody staining of CD94/NKG2C expressing cells does not sup-
port this conclusion.
pQa-1 expression inhibits NK cells by engagement of the CD94/NKG2A
receptor
We next examined the effect of pQa-1 surface expression on NK activation ex vivo. Murine C57BL/6
splenocytes were isolated and co-cultured with CHO cells expressing vector only (CHO-V), Qa-1 or
pQa-1, either wildtype (CHO-pQa-1) or pQa-1-SCT (CHO-pQa-1-SCT) (Figure 6—figure supple-
ment 6–1A). CHO cells are prototypic targets of C57BL/6 NK cells and can stimulate NK cells to
release cytotoxic granules and cytokines through the Ly49D activation receptor (Idris et al., 1999).
Of note, lysosomal-associated membrane protein-1 (LAMP-1, CD107a) is a membrane component of
cytotoxic granules that was recently described as a functional marker for NK degranulation, a critical
step in target cell lysis (Alter et al., 2004). Thus, to distinguish activity of NKG2A+ NK cells from
NKG2A- NK cells, IFNg and CD107a expression was analyzed using flow cytometry in the two NK
populations after incubation with the indicated CHO cells.
A dose-dependent effect was observed in both types of NK cells upon incubation with increasing
number of CHO cells, but the ratio of NK activation of NKG2A+ to NKG2A- was stable with different
amounts of offered CHO cells. A one to one ratio was therefore used to analyze the effect of Qa-1
or pQa-1 on NKG2A+ NK activation. When cultured with CHO-pQa-1 cells in the presence of Qdm
or Qdm-k peptide, but not a peptide that cannot stabilize surface pQa-1, mouse spleen NKG2A+
NK cells showed less IFNg production than NKG2A- cells, which was not the case upon culture with
control CHO-V cells (Figure 6A and B). A similar decrease in IFNg production was observed when
NK cells were incubated with CHO cells expressing the natural NKG2A ligand Qa-1 (Figure 6A and
B), suggesting that an inhibitory effect comparable to mouse Qa-1 on NK activity was mediated by
the expression of viral pQa-1. In addition, like Qa-1, this suppressive effect could be reversed by the
NKG2A/C/E blocking antibodies but not by an isotype control, demonstrating that pQa-1 exerts its
effect specifically through the NKG2A receptor (Figure 6C). Furthermore, compared with the inhibi-
tory effect mediated by CHO-pQa-1 or CHO-Qa-1 cells, CHO cells expressing pQa-1-SCT showed
significantly stronger suppression on NKG2A+ NK cells in IFNg production as well as CD107a
Figure 4 continued
(as depicted by cartoons) on MER cells in the presence of vector or pK3 were analyzed. Quantification of median fluorescence intensity (MFI) in (A and
B) or relative surface levels in (C) from two to four analyses are shown as bars with mean ±SEM. Unpaired t test or one-way ANOVA Dunnett’s multiple
comparisons test was used (*=p < 0.05; **=p < 0.01; ***=p < 0.001; ****=p < 0.0001; ns = not significant).
DOI: https://doi.org/10.7554/eLife.38667.007
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Figure 5. The Qdm-b2m-pQa-1 single chain trimer (SCT) specifically recognizes the CD94/NKG2A receptor. (A) Spleen lymphocytes isolated from
wildtype C57BL/6 or NKG2A-/- knockout mice were stained with PE-labeled pQa-1-dtSCT tetramer (PE-pQa-1 Tet), or PE-labeled streptavidin (PE-SA) as
negative control, at room temperature for 1 hr followed by staining with a mixture of fluorochrome labeled antibodies containing either anti-NKG2A/C/
E (20D5) or isotype control for 30 min. The stained cells were acquired by BD Canto II and data were analyzed with FlowJo software. Representative
data of four (wildtype) and two (NKG2A-/-) independent experiments are shown. NK cells were defined as the live NK1.1+CD3-CD19- population, while
CD8 T cells were gated on the live CD19- CD3+CD8+ population.
DOI: https://doi.org/10.7554/eLife.38667.008
The following figure supplements are available for figure 5:
Figure supplement 1. pQa-1 single chain trimer design and increased thermal stability.
DOI: https://doi.org/10.7554/eLife.38667.009
Figure supplement 2. pQa-1-dtSCT tetramer stains CD94/NKG2A expressing cells stronger than CD94/NKG2C-expressing cells.
DOI: https://doi.org/10.7554/eLife.38667.010
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Figure 6. Expression of pQa-1 bound with Qdm/Qdm-like peptide inhibits NKG2A+ NK cell activation and prevents tumor rejection in vivo. C57BL/6
splenocytes were co-cultured with CHO cells expressing the indicated constructs and the NK cells were subsequently analyzed by flow cytometry (A–F).
The ratio of IFNg production between NKG2A+ and NKG2A- NK cells is shown in the bar graphs. (A) Representative dot plots of NK cell IFNg
production upon stimulation with CHO cells expressing vector, pQa-1, or Qa-1 in the presence of Qdm-k peptide (AMVPRTLLL). (B) Splenocytes were
co-cultured with indicated CHO cells in the presence of Qdm-k or control peptide. (C) Co-cultures were performed as in (B) in the presence of isotype
or 20D5 (anti-NKG2A/C/E) antibody. (D) IFNg and (E) CD107a expression by NK cells in response to CHO cells expressing pQa-1 single chain trimer
(pQa-1-SCT) was performed as in (C). (F) Same experiment as in (D) and (E) was conducted after CHO-pQa-1-SCT and CHO-V cells were treated with or
without 0.5 U/ml PI-PLC. (A–F) Representative experiments are shown from two to three independent experiments per panel. Bars in the figures
represent mean ±SEM of duplicates. (G) 5000 Qa-1-restricted Ln12 T cells were co-cultured overnight with titrating amounts of human T2 cells (TAP-
deficient cells) expressing vector, Qa-1, or pQa-1. The amount of IFNg in the supernatants was determined by ELISA. EC7.1-Qa-1, a mouse TAP- and
Figure 6 continued on next page
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expression, which again could be blocked by the NKG2A/C/E-specific antibody (Figure 6D and E).
This inhibitory effect could not be altered by the addition of Qdm peptide since Qdm is tethered to
Qa-1 in the SCT format. Thus, pQa-1-SCT is functionally potent in inducing NKG2A-mediated NK
cell inhibition which correlates well with its increased surface expression and thermostability (Fig-
ure 5—figure supplement 5–1). These findings are in agreement with the binding specificity of
pQa-1 determined using pQa-1-dtSCT tetramer (Figure 5). To further assess whether inhibition of
NKG2A+ NK cells is mediated by pQa-1, CHO-V and CHO-pQa-1-SCT cells were treated with or
without PI-PLC before co-culture with mouse spleen cells. We observed increased NKG2A+ NK cell
activation, as measured by IFNg production and CD107a degranulation, when CHO-pQa-1-SCT was
cleaved off the cell surface (Figure 6F and Figure 6—figure supplement 6–1A). Taken together,
these data demonstrate that pQa-1 can functionally mimic Qa-1 to mediate inhibition of NK cells by
specific engagement of the inhibitory receptor CD94/NKG2A.
pQa-1 does not mimic antigen presentation to a Qa-1-restricted CD8+ T
cell clone
Recent reports suggest that HLA-E/Qa-1 can activate HLA-E/Qa-1 restricted CD8+ T cells by pre-
senting pathogen-derived or unconventional self-peptides (Hansen et al., 2016; Bian et al., 2017;
Oliveira et al., 2010), which likely occurs when canonical MHC-I antigen presentation is impaired
(Oliveira et al., 2010; Nagarajan et al., 2012; Lampen et al., 2013). Given this potential, we exam-
ined whether pQa-1 might ‘unintentionally’ activate Qa-1-restricted CD8+ T cells. For this purpose,
we used a well-characterized Qa-1-restricted CD8+ T cell clone, Ln12 (Doorduijn et al., 2018). Co-
culturing T2-Qa-1 cells, the TAP-deficient cell line transduced to express Qa-1 (Figure 6—figure
supplement 6–1B) with Ln12 cells resulted in significant IFNg production in a dose-dependent man-
ner. However, under the same conditions, using T2 cells expressing pQa-1 (Figure 6—figure supple-
ment 6–1B) we observed no T-cell activation (Figure 6G). Thus, it appears that in contrast to its
mimicry of Qa-1 in CD94/NKG2A interactions, viral pQa-1 may not conserve antigen presentation
properties with Qa-1.
pQa-1 expression can protect cells from NK killing in vivo
The capacity of pQa-1 to provide protection in vivo was assessed in a murine melanoma metastasis
model. B16F10 melanoma cells, which can establish metastasis in the lungs of C57BL/6 mice when
NK control is subverted (Takeda et al., 2011), were transduced to express either empty vector alone
(B16-V) or pQa-1-dtSCT (B16-pQa-1-dtSCT) (Figure 6—figure supplement 6–1C). The two resulting
cell lines displayed no difference in proliferation in vitro. In vivo, B16F10 metastasis formation was
prevented by NK cells as NK cell depletion with anti-NK1.1 resulted in high numbers of metastatic
lesions 2 weeks after intravenous injection of the tumor cells (Figure 6H, compare B16-V to B16-
V + anti-NK1.1). Consistent with the inhibitory effect of pQa-1 on NK cell activation in vitro, chal-
lenge of C57BL/6 mice with B16F10-pQa-1-dtSCT cells resulted in at least two-fold more lung
metastases compared to mice challenged with B16F10 cells expressing empty vector (Figure 6H).
These data thus demonstrate that pQa-1 has the capacity to protect cells from NK control in vivo.
Downregulation of MHC-I by pK3 increases cell susceptibility to NK
killing that can be subverted by pQa-1 co-expression
To experimentally assess if pK3-induced downregulation of MHC-I and Qa-1 can lead to NK activa-
tion and that pQa-1 functions to counteract these effects on NK cells, we transduced RMA cells with
Figure 6 continued
MHC-Ia-deficient lymphoma cell line transduced to express Qa-1 served as a positive control. Mean ±SD of triplicates is shown. (H) Lung metastasis
formation 14 days after intravenous injection B16F10 melanoma cells expressing pQa-dtSCT or vector control (B16-pQa-1 or B16-V). Dots over each bar
represent individual mice, cumulative data from two independent experiments. Two-tailed unpaired t test was used (*=p < 0.05; **=p < 0.01).
DOI: https://doi.org/10.7554/eLife.38667.011
The following figure supplement is available for figure 6:
Figure supplement 1. Surface level of pQa-1 or Qa-1 on cells used in the assays in Figure 6.
DOI: https://doi.org/10.7554/eLife.38667.012
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either pK3 or the pK3 RING mutant. As expected, expression of pK3, but not pK3 RM induced dra-
matic reduction of surface classical MHC-I molecules as well as Qa-1 (Figure 4B and Figure 7—fig-
ure supplement 7–1). When cultured with syngeneic NK cells from mouse spleen, a significantly
higher percentage of cells expressing pK3 were killed than cells expressing the pK3 RING mutant,
demonstrating that a decrease of surface MHC-I induced by pK3 rendered cells susceptible to NK
killing (Figure 7A). Moreover, in comparison to cells expressing only pK3, cells co-expressing pQa-1
with pK3 showed reduced susceptibility to NK cell killing. This reduction was not evident when NK
cells from NKG2A-/- mice were used, indicating the protection provided by expression of pQa-1 is
mediated by engagement of CD94/NKG2A (Figure 7A). Consistently, a small decrease in pQa-1 sur-
face expression on target cells after PI-PLC treatment was found to correlate with a modest increase
in NK killing (Figure 7—figure supplement 7–2). Together these data indicate that resistance of
pQa-1 to pK3 is functionally important and suggest that RHVP has evolved a mechanism for thwart-
ing ‘missing self’ recognition by NK cells. Collectively, our findings allow us to propose a model for
how RHVP expresses two proteins that work in concert to evade CTL and NK killing (Figure 7B).
Discussion
In this report, we identified and functionally characterized an RHVP encoded protein that can inhibit
NK killing through direct engagement of CD94/NKG2A receptors. Although manipulation of host
HLA-E/Qa-1 surface expression has been reported as a NK evasion strategy by other viruses, a viral
mimic of Qa-1 has not been previously noted. The pQa-1 ORF is unusual in that the mRNA is pro-
duced by splicing of a primary transcript with an exon structure analogous to that found in mamma-
lian MHC-I. The putative a1–3 domains of pQa-1 have >56% sequence identity to mouse and rat
Qa-1, and it conserves the functional characteristics of Qa-1 including association with b2m and low
level cell surface expression stabilized by Qdm or Qdm-like peptides. More impressively, pQa-1
mimics Qa-1 function by effectively engaging the inhibitory NK receptor CD94/NKG2A, yet is resis-
tant to downregulation by the RHVP encoded MHC-I subversion protein pK3. These findings empha-
size the collaboration between CTL and NK activation in control of RHVP infection and bring
additional insight into the impact of host/pathogen interactions during coevolution.
The ability of herpesviruses to utilize RNA splicing as a means to expand their coding capacity
was not appreciated until recently (Stern-Ginossar et al., 2012; Conrad, 2009). The development
of next-generation sequencing techniques helped to uncover this viral strategy. For example,
through mRNA-sequencing, up to 27 splicing junctions, corresponding to one or more introns in 17
viral genes (20% of genes) of KSHV were identified and seven of them were previously unrecognized
(Arias et al., 2014). While the genome of RHVP was previously annotated to have three ORFs with
sequence similarity to MHC-I (Loh et al., 2011), we now have shown that this region encoding pQa-
1 has three consecutive exons separated by consensus splice donor and acceptor sites from which
two short introns are removed. Our observation of spliced messenger RNA from RHVP is similar to
what has been observed in KSHV, suggesting that the actual coding capacity and protein repertoire
of g herpesviruses is likely larger and more elaborate than was previously appreciated.
The high degree of similarity in both sequence and function between pQa-1 and Qa-1 along with
the conservation of the intron splicing sites suggest that the coding sequence of pQa-1 was acquired
by horizontal transfer. This is clearly distinct from other known viral MHC-I-like proteins that have
been previously identified in b herpesviruses and implicated in CTL or NK evasion (Revilleza et al.,
2011). Those viral MHC-I-like proteins, such as members of the m145 family of MCMV and UL18 of
HCMV, possess a common MHC-I fold but are highly divergent in amino acid sequence (25% iden-
tity). In addition, their mRNA transcripts are not spliced, suggesting they may have been acquired
from host transcripts as has been shown in other dsDNA viruses (Grossegesse et al., 2017;
Greijer et al., 2000; Bresnahan and Shenk, 2000).
In contrast to Qa-1 and MHC-I proteins, pQa-1 lacks a canonical TM region and cytoplasmic tail.
Its hydrophobic C terminus is removed during processing of the nascent protein with attachment of
a GPI moiety, which is associated with resistance to the RHVP CTL evasion protein pK3 that appears
to recognize classical and non-classical MHC-I by specific TM region interactions. This property of
pQa-1 is physiologically significant. In this study, we demonstrate that expression of pK3 renders
cells sensitive to NK killing that can be partly reversed by co-expression of pQa-1. A similar strategy
exists in the host to counteract viral immune evasion proteins. For example, distinct from other
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Figure 7. Downregulation of MHC-I by pK3 leads to NK killing susceptibility, while pQa-1 co-expression provides
protection in an NKG2A-dependent manner. (A) The GFP+ target cells (RMA cells expressing pK3 or pK3 RM by
IRES-GFP vector or co-expressing pK3 and pQa-1) were mixed with the effectors (NK cells isolated from wildtype
C57BL/6 or NKG2A-/- mice and activated by IL-2 for 6 days) at indicated E:T ratio and cultured at 37˚C for 4 hr
before stained with propidium iodide (PI) and analyzed by flow cytometry. NK killing%=[PI+ target %/(PI+ target%
+PI- target%)*100]. Bars represent mean ±SD of four replicates. Dunnett’s multiple comparisons test is used. (B)
Working model for how RHVP-encoded pK3 and pQa-1 work in concert to evade CTL and NK killing. In normal
circumstances, cytotoxic lymphocytes can survey foreign antigen through TCR recognition of MHC-I/peptide
complexes at the cell surface, and NK cells can sense defects in antigen presentation and processing via
engagement of HLA-E/Qa-1 by the inhibitory receptor CD94/NKG2A (left panel). In RHVP-infected cells, pK3
induces rapid degradation of MHC-I in the ER thus preventing CTL activation and clearance of infected cells; On
the other hand, pQa-1 lacks an MHC-I like TM region and is thus resistant to pK3, which allows its cell surface
expression and CD94/NKG2A engagement thus undermining ‘missing self’ recognition by NK cells (right panel).
DOI: https://doi.org/10.7554/eLife.38667.013
The following figure supplements are available for figure 7:
Figure supplement 1. Surface level of endogenous Qa-1, MHC-I and transduced pQa-1 on RMA cells expressing
pK3 or pK3 RING mutant (pK3 RM).
Figure 7 continued on next page
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alleles that possess a TM and a cytoplasmic tail, MICA*008, the most frequently expressed allele of
MICA in diverse populations worldwide, is GPI-anchored which is associated with its resistance to
kK5, a MARCH ubiquitin E3 ligase similar to the pK3 encoded by KSHV. kK5-mediated downregula-
tion of MICA requires lysine residues in the cytoplasmic tail of MICA for ubiquitination and subse-
quent internalization (Thomas et al., 2008; Ashiru et al., 2009). Thus, replacement of canonical TM
and cytoplasmic tail with GPI anchor appears to be an adaptive modification to avoid harmful recog-
nition events in both pathogens and hosts.
Compared to b herpesviruses in which multiple proteins function to evade CTL and NK detec-
tion, most g herpesviruses in the genus rhadinovirus employ less complex strategies to avoid attack
by CTL, and their NK evasion mechanisms are not well understood. A major CTL evasion mechanism
in rhadinoviruses is carried out by a group of MARCH family ubiquitin ligases (Hansen and Bouvier,
2009). Notably, although they share similar domain organization and have MHC-I molecules as com-
mon targets for rapid degradation, the detailed mechanisms underlining how these viral MARCH
ligases specifically recognize their substrates and where the degradation takes place are significantly
different. For example, kK5 and kK3 of KSHV target mature MHC-I by conjugating a K63-linked ubiq-
uitin chain on the tail of mature MHC-I heavy chain, which results in rapid endocytosis of MHC-I com-
plex followed by its degradation in the lysosome (Duncan et al., 2006). In contrast, mK3 of gHV68
acts at an earlier point in MHC class I biosynthesis (Boname and Stevenson, 2001; Yu et al., 2002).
It targets TAP-associated MHC-I in the ER by direct interaction with TAP, which results in K48-linked
ubiquitination and subsequent degradation of MHC-I by the proteasome. While pK3 of RHVP also
targets newly synthesized MHC-I for ER-associated degradation, it specifically recognizes the TM
region of the MHC-I heavy chains. Functionally, pK3 not only induces dramatic loss of MHC-I but
also TAP and tapasin (Herr et al., 2012).
As compared to the molecular mechanisms involved in MHC-I downregulation by the viral
MARCH E3 ligases, KSHV, gHV68 and RHVP appear to have divergent strategies to avoid NK attack.
For example, other than selectively targeting MHC-I to maintain expression of HLA-E, kK5 also
downregulates MICA and MICB, the ligands of conserved activating NK receptor NKG2D, to evade
NK cell cytotoxicity (Thomas et al., 2008). In addition, KSHV produces a miRNA that targets MICB
at the transcriptional level (Nachmani et al., 2009). In contrast to kK3 and kK5, the target spectrum
of mK3 is limited. It binds primarily TAP and only targets MHC-I heavy chains that are associated
with TAP/tapasin complex (Lybarger et al., 2003). There have been no MHC-I-like proteins or NK
inhibitory mechanisms identified in the genome of gHV68 thus far. In the case of RHVP, pK3 induces
significant downregulation of classical MHC-I as well as Qa-1, yet it encodes a GPI anchored Qa-1-
like protein that can suppress NKG2A+ NK cells. Collectively these observations support the hypoth-
esis that NK evasion strategies in g herpesviruses evolve with selection pressure imposed by CTL
evasion and are intimately linked to the CTL subversion mechanisms employed by the virus.
In addition to its function in innate immunity, HLA-E/Qa-1 has been reported to play a role in
adaptive immunity against intracellular pathogens or tumors by presenting microbial-derived pepti-
des or self-peptides other than Qdm to HLA-E/Qa-1-restricted CD8+ T cells (van Hall et al., 2010;
Joosten et al., 2016; Kraemer et al., 2014). Whether pQa-1 can also be recognized by Qa-1-
restricted CD8+ T cells, which would be beneficial to the host but detrimental to the virus, may
require further investigation in the context of viral infection. Nevertheless, our data show that pQa-1
expressed by a human TAP-deficient cell line does not activate a representative Qa-1-restricted T
cell clone as does Qa-1. Further, the acidic alpha-3 domain CD loop (Figure 1—figure supplement
1–2) critical for interaction with CD8 (Connolly et al., 1990; Chang et al., 2005; Wang et al., 2009)
and shared by classical MHC-I and Qa-1 is not conserved in pQa-1. Taken together it appears that in
contrast to its mimicry of Qa-1 in CD94/NKG2A engagement, viral pQa-1 may not conserve the
T-cell presentation features of cellular Qa-1. In summary, our findings reveal a novel NK evasion
Figure 7 continued
DOI: https://doi.org/10.7554/eLife.38667.014
Figure supplement 2. PI-PLC treatment diminishes pQa-1 mediated protection of RMA target cells expressing
pK3.
DOI: https://doi.org/10.7554/eLife.38667.015
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mechanism in which a virus encodes a Qa-1-like protein capable of counteracting its CTL sabotage
while retaining the ability to inhibit NK activity.
Materials and methods
Key resources table
Reagent
type (species)
or resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(M. musculus)
Klrc1-/- PMID: 26680205 Dr. Marco Colonna
laboratory
(Washington University
School of Medicine)
Strain, strain
background
(M. musculus)
C57BL/6NCr Charles River
Laboratories
Strain code: 556
Cell line
(M. musculus)
B6/WT-3 Dr. Stephen R Jennings
(Louisiana State University
Health Sciences Center);
PMID: 6316651
an SV-40 transformed,
C57BL/6 murine
embryo fibroblasts line
Cell line
(M. musculus)
BWZ.36 Dr. Nilabh Shastri
(University of California,
Berkeley); PMID:8186188
a mouse T
lymphoma line
Cell line
(M. musculus)
FT1- (Tap1-/-) Dr. Michael Edidin
(Johns Hopkin University);
PMID:10485658
a fibroblast line
derived from Tap1
knockout mice
Cell line
(M. musculus)
3KO (H2-K-/-, H2-D-/-,
B2m-/- murine
embryo fibroblast line)
Dr. Ted H. Hansen
laboratory;
PMID:12530981
3KO mice were derived
by breeding H2-Kb/-Db
doubly deficient
mice (PMID:10229092)
with B2m-/- mice
(Jackson Laboratories)
Cell line
(Homo sapiens)
T2 (174 x CEM.T2) American Type
Culture Collection
ATCC
CRL-1992,
RRID:CVCL_2211
a TAP deficient
T-B lymphoblast
hybrid (PMID: 3522223)
Cell line
(M. musculus)
RMA PMID: 3877776 RRID:CVCL_J385
Cell line
(M. musculus)
B16-F10 American Type
Culture Collection
ATCC
CRL-6475,
RRID:CVCL_0159
Cell line
(Cricetulus griseus)
CHO Dr. Pamela Stanley
laboratory (Albert
Einstein
College of Medicine)
Cell line
(Homo sapiens)
293F (FreeStyle
293 F Cells)
Thermo Fisher Scientific R79007,
RRID:CVCL_D603
Cell line
(Homo sapiens)
293T (HEK 293T) American Type
Culture Collection
ATCC
CRL-3216,
RRID:CVCL_0063
Antibody FITC labeled
anti-mouse
NKG2A/C/E
eBioscience cat# 11-5896-82 clone: 20D5
(1:100)
Antibody FITC labeled isotype
control (RatIgG2a)
eBioscience cat# 11-4321-85 clone: eBR2a
(1:100)
Antibody eFluor 660 labeled
anti-mouse CD107a
eBioscience cat# 50-1071-82 clone: eBio1D4B
(1:1000 in culture)
Antibody APC-eFluor labeled
anti-mouse CD19
eBioscience cat# 47-0193-82 clone: eBio
1D3 (1:100)
Antibody PE-Cy7 labeled
anti-mouse CD19
eBioscience cat# 25-0193-82 clone: eBio1D3
(1:200)
Continued on next page
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Continued
Reagent
type (species)
or resource Designation
Source or
reference Identifiers
Additional
information
Antibody APC-eFluor 780
labled anti-mouse
CD3e
eBioscience cat# 47-0031-82 clone: 145–2 C11
(1:100)
Antibody Pacific Blue labeled
anti-mouse CD3e
Biolegend cat# 100214 clone: 17A2
(1:100)
Antibody PE-eFluor 610
labeled anti-mouse
CD8a
eBioscience cat# 61-0081-80 clone: 53–6.7
(1:200)
Antibody PE labeled
anti-mouse CD94
eBioscience cat# 12-0941-82 clone: 18D3
(1:100)
Antibody mouse anti-HA tag Covance cat# MMS-101P clone: 16B12
(1:500)
Antibody eFluor 450 labeled
anti-mouse IFNg
eBioscience cat# 48-7311-82 clone:
XMG1.2 (1:100)
Antibody PE-Cy7 labeled
anti-mouse NK1.1
eBioscience cat# 25-5941-82 clone:
PK136 (1:100)
Antibody PerCp Cy5.5 labeled
anti-mouse NK1.1
eBioscience cat# 45-5941-82 clone: PK136
(1:200)
Antibody PE-labeled
anti-mouse Thy1.1
BD PharMingen cat# 551401 clone: OX-7
(1:150)
Antibody biotin labeled
anti-mouse Qa-1
BD PharMingen cat# 559829 clone:
6A8.6F10.1A6
(1:200)
Recombinant
DNA reagent
pMIG_pQa-1-HA current study Schematic
depiction
is shown in
Figure 2A
Recombinant
DNA reagent
pMIN_pQa-1-HA current study pMSCV.IRES.neo (pMIN)
was described
previously
(PMID:15280476)
Recombinant
DNA reagent
pMIG_pK3 PMID:22403403 Dr. Ted H Hansen
laboratory
Recombinant
DNA reagent
pMIN_Qa-1 current study DNA sequence
encoding
Qa-1b (NM_034528)
was subcloned
into pMIN vector
Recombinant
DNA reagent
pMIG_pQa-1-SCT current study Schematic depiction
is shown in
Figure 5—figure supplement 1
Recombinant
DNA reagent
pFM1.2R_pQa-
1-SCT-BirA
current study Described in
the DAN constructs
section in
Materials and methods
Peptide,
recombinant
protein
pQa-1-SCT current study Described in the
Production of
pQa-1-SCT Proteins
and Tetramers
section in Materials
and methods
Commercial
assay or kit
EasySep mouse NK
cell isolation kit
StemCell
Tecknologies
cat# 19815
Continued on next page
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Continued
Reagent
type (species)
or resource Designation
Source or
reference Identifiers
Additional
information
Chemical
compound, drug
PI-PLC
(phosphatidylinositol
-specific
phospholipase C)
Sigma P8804
Software,
algorithm
PHYLIP Neighbor
Joining algorithm
http://evolution.
genetics.washington.
edu/phylip/phylipweb.
html
Others rodent herpesvirus
Peru (RHVP)
PMID: 21209105 Dr. Herbert
W. Virgin laboratory
in Washington
University School
of Medicine
DNA constructs
Two retroviral expression vectors, pMSCV.IRES.GFP (pMIG) and pMSCV.IRES.neo (pMIN) used for
stable expression of pK3, Qa-1 and pQa-1-HA were described previously (Lybarger et al., 2003;
Wang et al., 2004). The pQa-1 sequence was obtained from RHVP-infected MEF cells by RT-PCR.
An HA tag was engineered in between the putative a3 domain and the last 26 amino acids (aa)
(Figure 2A). The Ld-pQa-1 chimeric construct was made by fusing the sequence of H2-Ld a1–3 to
the C-terminal 26aa of pQa-1. The pQa-1-SCT construct consists of, beginning at the N terminus,
the signal peptide of pQa-1, the Qdm peptide (AMAPRTLLL), linker1 (GGGASGGGGSGGGGS), the
mature mouse b2m, linker2 ((GGGGS)4) and the mature pQa-1-HA or the mature pQa-1 lacking the
last 26aa followed by the BirA recognition peptide (GSTGLNDIFEAQKIEWHE). The HA-tagged pQa-
1-SCT was expressed from the pMIG vector for surface expression in mammalian cells while the
BirA-peptide-tagged version of pQa-1-SCT was produced from the pFM1.2R vector in 293F cells for
biotin labeling (Nelson et al., 2014). All the constructs were confirmed by DNA sequencing.
Cell lines and mice
Murine embryonic fibroblast B6/WT-3 (MEF), b2m-deficient cells (B2m-/-), TAP1-deficient cells
(Tap1-/-, FT1-) and triple knockout fibroblasts (H2-Kb-/- H2-Db-/- b2m-/-; 3KO) were previously
described (Lybarger et al., 2003) and of C57BL/6 (H-2b) origin. Mouse RMA cells, B16F10, 293T
and 293F were obtained from ATCC or Thermo Fisher Scientific. The BWZ.36 line was kindly pro-
vided by Dr. Nilabh Shastri (UC, Berkeley). CHO cell line is a gift from Dr. Pamela Stanley (Albert Ein-
stein College of Medicine, NY). All cell lines have been assessed as mycoplasma negative. The pK3,
pQa-1 and b2m were stably expressed in the indicated cells by pMIG or pMIN and were enriched or
selected for GFP expression or neomycin resistance, respectively. 293F cells were cultured in Free-
Style 293F expression medium (Gibco). All the other cells were cultured in complete RPMI1640 or
DMEM (supplemented with 100 Unit/ml Penicillin–Streptomycin, 2 mM L-glutamine, 10 mM Hepes
and 10% FBS) in a 5% CO2 atmosphere at 37˚C. C57BL/6 mice were purchased from Charles River
laboratories, NKG2A-/- (Klrc1-/-) mice (Rapaport et al., 2015) bred and housed in specific pathogen-
free conditions in the accredited animal facilities at Washington University were a gift of Dr. Marco
Colonna.
Peptide-binding assay and peptides
MEF-pQa-1 cells were seeded in culture plates at 5  105 cells/ml. After overnight incubation at
37˚C, peptides were added into the culture to a final concentration of 100 mM and incubated at
27˚C, a condition known to promote peptide binding to classical MHC-I molecules (Hansen and
Myers, 2003). Four hours later the cells were subjected to flow cytometric analysis. The OVA-
derived peptide (SIINFEKL) (Carbone and Bevan, 1989), Qdm peptide (AMAPRTLLL), and others
used for peptide binding (Supplementary file 2) were synthesized by GenScript (Piscataway, NJ).
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Production of pQa-1-SCT proteins and tetramers
Biotinylated soluble pQa-1-SCT or pQa-1-dtSCT monomer was produced by transient transfection
of 293 F cells with the corresponding plasmid DNA as previously described (Nelson et al., 2014).
The secreted protein containing a C-terminal 6His tag was purified from culture medium using Ni-
agarose beads (Qiagen) followed by size-exclusion chromatography on a HiLoaD 26/60 Superdex
200 pg column (GE Healthcare). The proteins were biotin labeled on an included BirA-peptide-tag
with enzyme in vitro following the manufacture’s protocol (Avidity). The labeled protein was tested
for biotinylation by ELISA using HRP conjugated streptavidin (Invitrogen), and then tetramerized
through addition of phycoerythrin (PE)-labeled streptavidin (SA) (BD Biosciences) at a molar ratio of
4 molecules of SCT monomers to 1 molecule of PE-SA.
Antibodies and flow cytometry analysis
Fluorescence-labeled antibodies including anti-NK1.1 (PK136), anti-NKG2A/C/E (20D5), anti-CD3
(145–2 C11), anti-CD19 (1D3), anti-CD8a (53–6.7), anti-CD107a (1D4B), anti-IFNg (XMG1.2), anti-
Thy-1.1 (OX-7), and isotype control were purchased from either eBioscience or BD Pharmingen.
Unconjugated antibodies anti-H2-Kb (B8-24-3) and anti-H2-Ld (30-5-7) were described
(Lybarger et al., 2003), anti-HA (16B12) and biotin-labeled anti-Qa-1 (6A8.6F10.1A6) were obtained
from Covance and BD Pharmingen, respectively.
Spleen cells were first stained with fixable viability stain 660 (BD Horizon) or fixable viability dye
eFluor 506 (eBioscience), followed by surface staining with directly conjugated antibodies diluted in
Fc block (2.4G2) or with unconjugated/biotinylated antibodies in two steps using fluorescence conju-
gated secondary antibodies or streptavidin (BD Pharmingen), respectively. When intracellular stain-
ing was involved, the above surface staining was followed by fixation, permeabilization and directly
conjugated antibody staining using Cytofix/Cytoperm kit (BD Biosciences) according to manufac-
turer’s protocol. Stained samples were analyzed by flow cytometry using BD FACS Calibur, BD FACS
Canto II or BD LSRFORTESSA X-20 and the data were analyzed with FlowJo software (Tree Star).
The pQa-1-dtSCT tetramer staining was conducted at room temperature for 1 hr prior to the anti-
body staining. NK cells were defined as viable, NK1.1+CD3-CD19-.
NK stimulation assay
Co-cultures of 4  106 C57BL/6 splenocytes and 1  105 CHO cells expressing vector only, pQa-1,
Qa-1, or pQa-1-SCT in the presence of 30 mM Qdm-k (AMVPRTLLL) peptide where indicated were
incubated under 5% CO2 atmosphere at 37˚C. Where indicated 10 mg/ml isotype or 20D5 (anti-
NKG2A/C/E) FITC-conjugated antibody was added to block the NKG2A-Qa-1 interaction. After 1 hr
of 1x monensin (eBioscience) treatment in culture, 0.2 mg/ml fluorescent anti-CD107a antibody was
added for an additional 5–8 hr. Cells were subsequently stained with fluorescent antibodies and ana-
lyzed by flow cytometry as described above.
Experimental lung metastasis
A total of 3  105/mouse B16F10 cells transduced to express either empty vector or pQa-1-dtSCT
were suspended in endotoxin-free PBS prior to i.v. injection into C57BL/6 mice. For NK-depletion
controls, mice were administered i.p. with 200 mg anti-NK1.1 mAb, 2 days before and 2 days after
B16F10 cell inoculation. After 14 days, the lungs were removed, PBS perfused and fixed with
Feteke’s solution (Overwijk and Restifo, 2001). The lung samples were blinded and the number of
lung tumor metastatic colonies was counted under a dissecting microscope.
NK cytotoxicity assay
NK cells were enriched from spleen cells of the indicated mice by negative selection using EasySep
mouse NK Iso kit (StemCell Tech) according to manufacturer’s instructions. After incubation in com-
plete DMEM supplemented with 800 Units IL-2 and 2  10 5 M 2-mercaptoethanol in 5% CO2 atmo-
sphere at 37˚C for 6–9 days, the adherent cells (NK purity >95%) were collected and co-cultured
with the indicated GFP+ target cells at an E:T ratio of 2-6:1 for 4 hr. All the cells were then stained
with propidium iodide (PI) 2–4 min before analysis by flow cytometry. Target killing%=[PI+ target%/
(PI+ target%+PI- target%)*100].
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Statistics
Statistical significance compared with a control group was calculated using ANOVA with Dunnett’s
multiple comparisons test, or unpaired t test, and annotated as *=p < 0.05; **=p < 0.01;
***=p < 0.001; ****=p < 0.0001.
Acknowledgements
We thank Nilabh Shastri (UC Berkeley) for the BWZ.36 cell line, Marco Colonna (Washington Univer-
sity) for providing NKG2A-/- mice, and Alexander Barrow for helpful discussion. This work is sup-
ported by NIH grant R01-AI109687.
Additional information
Competing interests
Wayne M Yokoyama: Reviewing editor, eLife. The other authors declare that no competing interests
exist.
Funding
Funder Grant reference number Author
National Institute of Allergy
and Infectious Diseases
R01-AI109687 Daved H Fremont
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Xiaoli Wang, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing—origi-
nal draft; Sytse J Piersma, Formal analysis, Investigation, Visualization, Methodology, Writing—origi-
nal draft; Christopher A Nelson, Conceptualization, Formal analysis, Visualization, Writing—review
and editing; Ya-Nan Dai, Eric Lazear, Formal analysis, Investigation; Ted Christensen, Formal analysis,
Investigation, Visualization; Liping Yang, Investigation, Methodology; Marjolein Sluijter, Formal anal-
ysis, Investigation, Methodology; Thorbald van Hall, Formal analysis, Investigation, Methodology,
Writing—review and editing; Ted H Hansen, Wayne M Yokoyama, Conceptualization, Supervision,
Funding acquisition, Writing—review and editing; Daved H Fremont, Conceptualization, Formal anal-
ysis, Supervision, Funding acquisition, Investigation, Writing—review and editing
Author ORCIDs
Thorbald van Hall http://orcid.org/0000-0002-9115-558X
Wayne M Yokoyama http://orcid.org/0000-0002-0566-7264
Daved H Fremont http://orcid.org/0000-0002-8544-2689
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of
the animals were handled according to the approved institutional animal care and use committee
(IACUC) protocol (#20130049). The protocol was approved by the Animal Studies Committee of
Washington University.
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.38667.019
Author response https://doi.org/10.7554/eLife.38667.020
Wang et al. eLife 2018;7:e38667. DOI: https://doi.org/10.7554/eLife.38667 21 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Additional files
Supplementary files
. Supplementary file 1. RHVP encodes a protein with high identity to Qa-1.
DOI: https://doi.org/10.7554/eLife.38667.017
. Supplementary file 2. Peptides used for pQa-1 surface stabilization assay.
DOI: https://doi.org/10.7554/eLife.38667.016
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
References
Alter G, Malenfant JM, Altfeld M. 2004. CD107a as a functional marker for the identification of natural killer cell
activity. Journal of Immunological Methods 294:15–22. DOI: https://doi.org/10.1016/j.jim.2004.08.008,
PMID: 15604012
Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D.
2014. KSHV 2.0: a comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using
next-generation sequencing reveals novel genomic and functional features. PLOS Pathogens 10:e1003847.
DOI: https://doi.org/10.1371/journal.ppat.1003847, PMID: 24453964
Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR. 2009. NKG2D ligand MICA is retained in the
cis-Golgi apparatus by human cytomegalovirus protein UL142. Journal of Virology 83:12345–12354.
DOI: https://doi.org/10.1128/JVI.01175-09, PMID: 19793804
Bai A, Broen J, Forman J. 1998. The pathway for processing leader-derived peptides that regulate the
maturation and expression of Qa-1b. Immunity 9:413–421. DOI: https://doi.org/10.1016/S1074-7613(00)80624-
X, PMID: 9768761
Bian Y, Shang S, Siddiqui S, Zhao J, Joosten SA, Ottenhoff THM, Cantor H, Wang CR. 2017. MHC Ib molecule
Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection
against infection. PLOS Pathogens 13:e1006384. DOI: https://doi.org/10.1371/journal.ppat.1006384, PMID: 2
8475642
Boname JM, Stevenson PG. 2001. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 15:
627–636. DOI: https://doi.org/10.1016/S1074-7613(01)00213-8, PMID: 11672544
Braud VM, Allan DS, Wilson D, McMichael AJ. 1998a. TAP- and tapasin-dependent HLA-E surface expression
correlates with the binding of an MHC class I leader peptide. Current Biology 8:1–10. DOI: https://doi.org/10.
1016/S0960-9822(98)70014-4, PMID: 9427624
Braud VM, Allan DS, O’Callaghan CA, So¨derstro¨m K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips
JH, Lanier LL, McMichael AJ. 1998b. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature
391:795–799. DOI: https://doi.org/10.1038/35869, PMID: 9486650
Bresnahan WA, Shenk T. 2000. A subset of viral transcripts packaged within human cytomegalovirus particles.
Science 288:2373–2376. DOI: https://doi.org/10.1126/science.288.5475.2373, PMID: 10875924
Carbone FR, Bevan MJ. 1989. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.
Journal of Experimental Medicine 169:603–612. DOI: https://doi.org/10.1084/jem.169.3.603, PMID: 2784478
Carrillo-Bustamante P, Kes¸mir C, de Boer RJ. 2016. The evolution of natural killer cell receptors.
Immunogenetics 68:3–18. DOI: https://doi.org/10.1007/s00251-015-0869-7, PMID: 26392015
Chang HC, Tan K, Ouyang J, Parisini E, Liu JH, Le Y, Wang X, Reinherz EL, Wang JH. 2005. Structural and
mutational analyses of a CD8alphabeta heterodimer and comparison with the CD8alphaalpha homodimer.
Immunity 23:661–671. DOI: https://doi.org/10.1016/j.immuni.2005.11.002, PMID: 16356863
Connolly JM, Hansen TH, Ingold AL, Potter TA. 1990. Recognition by CD8 on cytotoxic T lymphocytes is ablated
by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I
molecule. PNAS 87:2137–2141. DOI: https://doi.org/10.1073/pnas.87.6.2137
Conrad NK. 2009. Posttranscriptional gene regulation in Kaposi’s sarcoma-associated herpesvirus. Advances in
Applied Microbiology 68:241–261. DOI: https://doi.org/10.1016/S0065-2164(09)01206-4, PMID: 19426857
DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. 1997. Dominance of a single peptide bound to the
class I(B) molecule, Qa-1b. Journal of Immunology 158:2183–2191.
Doorduijn EM, Sluijter M, Querido BJ, Seidel UJE, Oliveira CC, van der Burg SH, van Hall T. 2018. T Cells
Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant
Lymphocytes. Frontiers in Immunology 9:60. DOI: https://doi.org/10.3389/fimmu.2018.00060, PMID: 29422902
Duncan LM, Piper S, Dodd RB, Saville MK, Sanderson CM, Luzio JP, Lehner PJ. 2006. Lysine-63-linked
ubiquitination is required for endolysosomal degradation of class I molecules. The EMBO Journal 25:1635–
1645. DOI: https://doi.org/10.1038/sj.emboj.7601056, PMID: 16601694
Fankhauser N, Ma¨ser P. 2005. Identification of GPI anchor attachment signals by a Kohonen self-organizing map.
Bioinformatics 21:1846–1852. DOI: https://doi.org/10.1093/bioinformatics/bti299, PMID: 15691858
Feng P, Moses A, Fru¨h K. 2013. Evasion of adaptive and innate immune response mechanisms by g-
herpesviruses. Current Opinion in Virology 3:285–295. DOI: https://doi.org/10.1016/j.coviro.2013.05.011
Wang et al. eLife 2018;7:e38667. DOI: https://doi.org/10.7554/eLife.38667 22 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Gays F, Fraser KP, Toomey JA, Diamond AG, Millrain MM, Dyson PJ, Brooks CG. 2001. Functional analysis of the
molecular factors controlling Qa1-mediated protection of target cells from NK lysis. The Journal of Immunology
166:1601–1610. DOI: https://doi.org/10.4049/jimmunol.166.3.1601, PMID: 11160201
Greijer AE, Dekkers CA, Middeldorp JM. 2000. Human cytomegalovirus virions differentially incorporate viral
and host cell RNA during the assembly process. Journal of Virology 74:9078–9082. DOI: https://doi.org/10.
1128/JVI.74.19.9078-9082.2000, PMID: 10982353
Grossegesse M, Doellinger J, Haldemann B, Schaade L, Nitsche A. 2017. A next-generation sequencing
approach uncovers viral transcripts incorporated in poxvirus virions. Viruses 9:296. DOI: https://doi.org/10.
3390/v9100296, PMID: 29027916
Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, Reed JS, Gilbride RM, Ainslie E,
Morrow DW, Ford JC, Selseth AN, Pathak R, Malouli D, Legasse AW, Axthelm MK, Nelson JA, Gillespie GM,
Walters LC, Brackenridge S, et al. 2016. Broadly targeted CD8+ T cell responses restricted by major
histocompatibility complex E. Science 351:714–720. DOI: https://doi.org/10.1126/science.aac9475, PMID: 267
97147
Hansen TH, Bouvier M. 2009. MHC class I antigen presentation: learning from viral evasion strategies. Nature
Reviews Immunology 9:503–513. DOI: https://doi.org/10.1038/nri2575, PMID: 19498380
Hansen T, Myers N. 2003. Peptide induction of surface expression of class I MHC. Current Protocols in
Immunology 18:11. DOI: https://doi.org/10.1002/0471142735.im1811s57, PMID: 18432904
Herr RA, Wang X, Loh J, Virgin HW, Hansen TH. 2012. Newly discovered viral E3 ligase pK3 induces endoplasmic
reticulum-associated degradation of class I major histocompatibility proteins and their membrane-bound
chaperones. Journal of Biological Chemistry 287:14467–14479. DOI: https://doi.org/10.1074/jbc.M111.325340,
PMID: 22403403
Hoare HL, Sullivan LC, Clements CS, Ely LK, Beddoe T, Henderson KN, Lin J, Reid HH, Brooks AG, Rossjohn J.
2008. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I
molecule HLA-E by the CD94-NKG2 natural killer cell receptors. Journal of Molecular Biology 377:1297–1303.
DOI: https://doi.org/10.1016/j.jmb.2008.01.098, PMID: 18339401
Idris AH, Smith HR, Mason LH, Ortaldo JR, Scalzo AA, Yokoyama WM. 1999. The natural killer gene complex
genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing. PNAS 96:6330–
6335. DOI: https://doi.org/10.1073/pnas.96.11.6330, PMID: 10339587
Jensen PE, Sullivan BA, Reed-Loisel LM, Weber DA. 2004. Qa-1, a nonclassical class i histocompatibility molecule
with roles in innate and adaptive immunity. Immunologic Research 29:081–092. DOI: https://doi.org/10.1385/
IR:29:1-3:081
Joosten SA, Sullivan LC, Ottenhoff THM. 2016. Characteristics of HLA-E restricted T-Cell responses and their
role in infectious diseases. Journal of Immunology Research 2016:1–11. DOI: https://doi.org/10.1155/2016/
2695396
Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. 2005. Interactions between
NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. The Journal of
Immunology 174:2878–2884. DOI: https://doi.org/10.4049/jimmunol.174.5.2878, PMID: 15728498
Kaiser BK, Pizarro JC, Kerns J, Strong RK. 2008. Structural basis for NKG2A/CD94 recognition of HLA-E. PNAS
105:6696–6701. DOI: https://doi.org/10.1073/pnas.0802736105, PMID: 18448674
Keller EB, Noon WA. 1984. Intron splicing: a conserved internal signal in introns of animal pre-mRNAs. PNAS 81:
7417–7420. DOI: https://doi.org/10.1073/pnas.81.23.7417, PMID: 6209716
Kraemer T, Blasczyk R, Bade-Doeding C. 2014. HLA-E: A novel player for histocompatibility. Journal of
Immunology Research 2014:1–7. DOI: https://doi.org/10.1155/2014/352160
Kraft JR, Vance RE, Pohl J, Martin AM, Raulet DH, Jensen PE. 2000. Analysis of Qa-1(b) peptide binding
specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexes. The Journal of
Experimental Medicine 192:613–624. DOI: https://doi.org/10.1084/jem.192.5.613, PMID: 10974028
Kurepa Z, Forman J. 1997. Peptide binding to the class Ib molecule, Qa-1b. Journal of Immunology 158:3244–
3251.
Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, de Ru AH, van der Burg SH, van Veelen PA, van
Hall T. 2013. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.
Molecular Immunology 53:126–131. DOI: https://doi.org/10.1016/j.molimm.2012.07.009
Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. 1996. Human natural killer cell receptors involved in MHC
class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. Journal of Immunology 157:
4741–4745.
Llano M, Lee N, Navarro F, Garcı´a P, Albar JP, Geraghty DE, Lo´pez-Botet M. 1998. HLA-E-bound peptides
influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-
derived nonamer. European Journal of Immunology 28:2854–2863. DOI: https://doi.org/10.1002/(SICI)1521-
4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W, PMID: 9754572
Loh J, Zhao G, Nelson CA, Coder P, Droit L, Handley SA, Johnson LS, Vachharajani P, Guzman H, Tesh RB, Wang
D, Fremont DH, Virgin HW. 2011. Identification and sequencing of a novel rodent gammaherpesvirus that
establishes acute and latent infection in laboratory mice. Journal of Virology 85:2642–2656. DOI: https://doi.
org/10.1128/JVI.01661-10, PMID: 21209105
Lubman OY, Cella M, Wang X, Monte K, Lenschow DJ, Huang YH, Fremont DH. 2014. Rodent herpesvirus Peru
encodes a secreted chemokine decoy receptor. Journal of Virology 88:538–546. DOI: https://doi.org/10.1128/
JVI.02729-13, PMID: 24173234
Wang et al. eLife 2018;7:e38667. DOI: https://doi.org/10.7554/eLife.38667 23 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Lubman OY, Fremont DH. 2016. Parallel evolution of chemokine binding by structurally related herpesvirus
decoy receptors. Structure 24:57–69. DOI: https://doi.org/10.1016/j.str.2015.10.018, PMID: 26671708
Lybarger L, Wang X, Harris MR, Virgin HW, Hansen TH. 2003. Virus subversion of the MHC class I peptide-
loading complex. Immunity 18:121–130. DOI: https://doi.org/10.1016/S1074-7613(02)00509-5, PMID: 12530
981
Mitaksov V, Truscott SM, Lybarger L, Connolly JM, Hansen TH, Fremont DH. 2007. Structural engineering of
pMHC reagents for T cell vaccines and diagnostics. Chemistry & Biology 14:909–922. DOI: https://doi.org/10.
1016/j.chembiol.2007.07.010, PMID: 17719490
Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. 2009. Diverse herpesvirus microRNAs target the stress-
induced immune ligand MICB to escape recognition by natural killer cells. Cell Host & Microbe 5:376–385.
DOI: https://doi.org/10.1016/j.chom.2009.03.003, PMID: 19380116
Nagarajan NA, Gonzalez F, Shastri N. 2012. Nonclassical MHC class Ib-restricted cytotoxic T cells monitor
antigen processing in the endoplasmic reticulum. Nature Immunology 13:579–586. DOI: https://doi.org/10.
1038/ni.2282, PMID: 22522492
Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. 2002. Structure and function of natural killer cell
receptors: multiple molecular solutions to self, nonself discrimination. Annual Review of Immunology 20:853–
885. DOI: https://doi.org/10.1146/annurev.immunol.20.100301.064812, PMID: 11861620
Nelson CA, McCoy WH, Fremont DH. 2014. Eukaryotic expression systems for structural studies. Methods in
Molecular Biology 1140:107–116. DOI: https://doi.org/10.1007/978-1-4939-0354-2_8, PMID: 24590712
Noriega V, Redmann V, Gardner T, Tortorella D. 2012. Diverse immune evasion strategies by human
cytomegalovirus. Immunologic Research 54:140–151. DOI: https://doi.org/10.1007/s12026-012-8304-8,
PMID: 22454101
Odom CI, Gaston DC, Markert JM, Cassady KA. 2012. Human herpesviridae methods of natural killer cell
evasion. Advances in Virology 2012:1–10. DOI: https://doi.org/10.1155/2012/359869
Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R,
van Hall T. 2010. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing
defects. The Journal of Experimental Medicine 207:207–221. DOI: https://doi.org/10.1084/jem.20091429,
PMID: 20038604
Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. 2002. Viral evasion of natural killer cells. Nature
Immunology 3:1006–1012. DOI: https://doi.org/10.1038/ni1102-1006, PMID: 12407408
Orange JS. 2013. Natural killer cell deficiency. Journal of Allergy and Clinical Immunology 132:515–525.
DOI: https://doi.org/10.1016/j.jaci.2013.07.020, PMID: 23993353
Overwijk WW, Restifo NP. 2001. B16 as a mouse model for human melanoma. Current Protocols in Immunology
20:1. DOI: https://doi.org/10.1002/0471142735.im2001s39, PMID: 18432774
Petrie EJ, Clements CS, Lin J, Sullivan LC, Johnson D, Huyton T, Heroux A, Hoare HL, Beddoe T, Reid HH, Wilce
MC, Brooks AG, Rossjohn J. 2008. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an
HLA class I leader sequence. The Journal of Experimental Medicine 205:725–735. DOI: https://doi.org/10.
1084/jem.20072525, PMID: 18332182
Rapaport AS, Schriewer J, Gilfillan S, Hembrador E, Crump R, Plougastel BF, Wang Y, Le Friec G, Gao J, Cella
M, Pircher H, Yokoyama WM, Buller RM, Colonna M. 2015. The Inhibitory Receptor NKG2A Sustains Virus-
Specific CD8+ T Cells in Response to a Lethal Poxvirus Infection. Immunity 43:1112–1124. DOI: https://doi.org/
10.1016/j.immuni.2015.11.005, PMID: 26680205
Revilleza MJ, Wang R, Mans J, Hong M, Natarajan K, Margulies DH. 2011. How the virus outsmarts the host:
function and structure of cytomegalovirus mhc-i-like molecules in the evasion of natural killer cell surveillance.
Journal of Biomedicine and Biotechnology 2011:1–12. DOI: https://doi.org/10.1155/2011/724607
Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic
Acids Research 42:W320–W324. DOI: https://doi.org/10.1093/nar/gku316, PMID: 24753421
Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, Burton RC, Shellam GR. 1992. The effect of the
Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells.
Journal of Immunology 149:581–589.
Stern-Ginossar N, Weisburd B, Michalski A, Le VT, Hein MY, Huang SX, Ma M, Shen B, Qian SB, Hengel H, Mann
M, Ingolia NT, Weissman JS. 2012. Decoding human cytomegalovirus. Science 338:1088–1093. DOI: https://
doi.org/10.1126/science.1227919, PMID: 23180859
Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, Okumura K, Smyth MJ. 2011. IFN-g
production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in
mice. Journal of Leukocyte Biology 90:777–785. DOI: https://doi.org/10.1189/jlb.0411208, PMID: 21712396
Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, Wills M, Lehner PJ. 2008. Down-regulation
of NKG2D and NKp80 ligands by Kaposi’s sarcoma-associated herpesvirus K5 protects against NK cell
cytotoxicity. PNAS 105:1656–1661. DOI: https://doi.org/10.1073/pnas.0707883105, PMID: 18230726
Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael
AJ, Wilkinson GW. 2000. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human
cytomegalovirus gpUL40. Science 287:1031–1033. DOI: https://doi.org/10.1126/science.287.5455.1031,
PMID: 10669413
Truscott SM, Lybarger L, Martinko JM, Mitaksov VE, Kranz DM, Connolly JM, Fremont DH, Hansen TH. 2007.
Disulfide bond engineering to trap peptides in the MHC class I binding groove. The Journal of Immunology
178:6280–6289. DOI: https://doi.org/10.4049/jimmunol.178.10.6280, PMID: 17475856
Wang et al. eLife 2018;7:e38667. DOI: https://doi.org/10.7554/eLife.38667 24 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Udenfriend S, Kodukula K. 1995. How glycosylphosphatidylinositol-anchored membrane proteins are made.
Annual Review of Biochemistry 64:563–591. DOI: https://doi.org/10.1146/annurev.bi.64.070195.003023,
PMID: 7574493
Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH. 2000. Cutting edge: the human
cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. The
Journal of Immunology 164:5019–5022. DOI: https://doi.org/10.4049/jimmunol.164.10.5019, PMID: 10799855
Vale´s-Go´mez M, Reyburn HT, Erskine RA, Lo´pez-Botet M, Strominger JL. 1999. Kinetics and peptide
dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/
NKG2-C to HLA-E. The EMBO Journal 18:4250–4260. DOI: https://doi.org/10.1093/emboj/18.15.4250,
PMID: 10428963
van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. 2010. The other Janus face of Qa-1 and HLA-E: diverse
peptide repertoires in times of stress. Microbes and Infection 12:910–918. DOI: https://doi.org/10.1016/j.
micinf.2010.07.011, PMID: 20670688
Vance RE, Jamieson AM, Raulet DH. 1999. Recognition of the class Ib molecule Qa-1(b) by putative activating
receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. The Journal of Experimental Medicine
190:1801–1812. DOI: https://doi.org/10.1084/jem.190.12.1801, PMID: 10601355
Wang X, Lybarger L, Connors R, Harris MR, Hansen TH. 2004. Model for the interaction of gammaherpesvirus 68
RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex.
Journal of Virology 78:8673–8686. DOI: https://doi.org/10.1128/JVI.78.16.8673-8686.2004, PMID: 15280476
Wang R, Natarajan K, Margulies DH. 2009. Structural basis of the CD8 alpha beta/MHC class I interaction:
focused recognition orients CD8 beta to a T cell proximal position. The Journal of Immunology 183:2554–2564.
DOI: https://doi.org/10.4049/jimmunol.0901276, PMID: 19625641
Yokoyama WM, Altfeld M, Hsu KC. 2010. Natural killer cells: tolerance to self and innate immunity to viral
infection and malignancy. Biology of Blood and Marrow Transplantation 16:S97–S105. DOI: https://doi.org/10.
1016/j.bbmt.2009.10.009, PMID: 19835969
Yu YY, Harris MR, Lybarger L, Kimpler LA, Myers NB, Virgin HW, Hansen TH. 2002. Physical association of the K3
protein of gamma-2 herpesvirus 68 with major histocompatibility complex class I molecules with impaired
peptide and beta(2)-microglobulin assembly. Journal of Virology 76:2796–2803. DOI: https://doi.org/10.1128/
JVI.76.6.2796-2803.2002, PMID: 11861847
Wang et al. eLife 2018;7:e38667. DOI: https://doi.org/10.7554/eLife.38667 25 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
